Cellectis SA (CLLS) has launched an replace.
Cellectis SA’s UCART22, a gene-edited CAR T-cell product candidate, has acquired Orphan Drug and Uncommon Pediatric Illness...
Editor's notice:Let's roundup the most-read Houston innovation information from the week. Trending Houston tech and startup articles from InnovationMap and its every day...